A Case of Sepsis Caused by Cellulitis in a Patient with Rheumatoid Arthritis after Tocilizumab Treatment
Journal of Rheumatic Diseases
; : 55-60, 2016.
Article
em En
| WPRIM
| ID: wpr-215897
Biblioteca responsável:
WPRO
ABSTRACT
Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, is therapeutically effective in patients diagnosed with rheumatoid arthritis (RA) compared with placebo. However patients treated with tocilizumab are at increased risk of several adverse effects including anaphylaxis and serious infections that may lead to hospitalization or death. Therefore, the risks and benefits of treatment with tocilizumab should be considered carefully and close monitoring of patients for development of signs and symptoms of side effects is required during and after treatment. Here, we report on a rare case of anaphylaxis and severe sepsis caused by cellulitis in a patient with RA after tocilizumab treatment.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Artrite Reumatoide
/
Celulite (Flegmão)
/
Interleucina-6
/
Sepse
/
Medição de Risco
/
Hospitalização
/
Anafilaxia
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Journal of Rheumatic Diseases
Ano de publicação:
2016
Tipo de documento:
Article